Obstructive Sleep Apnea
Conditions
Keywords
Obstructive Sleep Apnea, OSA, neurostimulation, hypoglossal nerve, tongue, upper airway stimulation, surgery
Brief summary
The purpose of this study is to obtain additional safety and efficacy data on the use of Inspire® therapy for the treatment of subjects with moderate to severe Obstructive Sleep Apnea.
Detailed description
This is a multi-center, prospective, single-arm study conducted under a common implant and follow-up protocol. Each subject will serve as their own control. The study will collect pre-operative two-night home sleep testing, medical history and subject quality of life measures. Intra- and post- operative procedure data will be collected. Therapy usage and device adjustment data, as well as a subject satisfaction with therapy survey, will be collected for additional analysis. Post-implant, procedure- and device-related events, QoL questionnaires, therapy usage and device adjustment data will be collected. Sleep study data will collected during the 2-month visit and, if conducted, a 3-month visit using a single night in-lab titration PSGs At 6 and 12 months post-implant, 2-night home sleep testing will be completed. Safety data will be collected throughout the study. Subjects will be exited from the study following the 12-month visits. The subject population will consist of otherwise healthy men and women that are at least 21 years old and have: 1) Provided written informed consent to participate, 2) Indicated a willingness to comply with study requirements for the specified follow-up duration, 3) Met all inclusion and exclusion criteria of this protocol. Up to 60 subjects will be implanted at up to 5 sites in Germany.
Interventions
This is a single-arm study; all participants will be implanted with the Inspire® Upper Airway Stimulation (UAS) System is a permanent, implantable therapy device, which consists of three implantable components: an IPG, a stimulation lead, and a sensing lead. In addition, the patient receives a remove to activate the therapy.
Sponsors
Inspire Medical Systems, Inc.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
Inspire Upper Airway Stimulation System
Eligibility
Sex/Gender
ALL
Age
21 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
1. Likely suffer moderate-to-severe OSA based on history and physical, or have an established diagnosis of OSA (≥ 15 AHI\<65) based on a prior sleep test 2. Willing and capable to have stimulation hardware permanently implanted, and to use the patient programmer to activate the stimulation 3. Willing and capable to return for all follow-up visits and conduct sleep studies at home, including the evaluation procedures and filling out questionnaires 4. Willing and capable of providing informed consent
Exclusion criteria
Contraindications 1. Any anatomical finding that would compromise the performance of upper airway stimulation, such as the presence of complete concentric collapse of the soft palate 2. Have any condition or procedure that has compromised neurological control of the upper airway 3. Unable or do not have the necessary assistance to operate the patient programmer 4. Pregnant or plan to become pregnant 5. Require magnetic resonance imaging (MRI) 6. Have an implantable device that may be susceptible to unintended interaction with the Inspire system. Additional exclusions for study purposes only: 7. Body Mass Index (BMI) of \> 35 8. Central + mixed apneas \> 25% of the total apnea-hypopnea index (AHI) 9. Any chronic medical illness or condition that contraindicates a surgical procedure under general anesthesia, as judged by the clinical study Investigator 10. Has a terminal illness with life expectancy \< 12 months 11. Active psychiatric disease (psychotic illness, major depression, or acute anxiety attacks) which prevents subject compliance with the requirements of the investigational study testing 12. Any other reason the investigator deems subject is unfit for participation in the study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Reported SAEs / Procedure & Device Related AEs | 12 months post-implant | Safety of the therapy will be assessed via the description of all reported SAEs and all procedure- or device-related AEs. Adverse events will be summarized by seriousness, severity, relatedness to the device and/or procedure and temporal relationship to the procedure. No formal statistical hypotheses will be tested. Only device- or procedure-related AEs will be collected in this post-market study. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change from Baseline OSA at 12 Months | 12 months post-implant | Frequencies and description statistics will be used to describe the data gathered in this study. A statistical comparison of pre-implant baseline and follow-up data may be performed. Efficacy endpoints will evaluate changes in subjects' quality of life (QoL) and Obstructive Sleep Apnea (OSA) severity through: 1. QoL: Epworth Sleepiness Scale: improvement from baseline to 12 months 2. QoL: Functional Outcomes of Sleepiness Questionnaire: improvement from baseline to 12 months 3. OSA Severity: Oxygen Desaturation Index: Reduction at 12 months as compared to baseline. 4. OSA Severity: Apnea Hypopnea Index: Reduction at 12 months as compared to baseline. |
Countries
Germany
Outcome results
None listed